EA201991147A1 - ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC - Google Patents
ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGCInfo
- Publication number
- EA201991147A1 EA201991147A1 EA201991147A EA201991147A EA201991147A1 EA 201991147 A1 EA201991147 A1 EA 201991147A1 EA 201991147 A EA201991147 A EA 201991147A EA 201991147 A EA201991147 A EA 201991147A EA 201991147 A1 EA201991147 A1 EA 201991147A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- nervous system
- central nervous
- increase
- sgc
- Prior art date
Links
- 210000003169 central nervous system Anatomy 0.000 title abstract 3
- 239000000021 stimulant Substances 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 abstract 6
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 abstract 3
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 abstract 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 abstract 2
- 230000033228 biological regulation Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Настоящее изобретение относится к применению стимуляторов растворимой гуанилатциклазы (sGC), их фармацевтически приемлемым солям и к фармацевтическим композициям или лекарственным формам, включающим эти стимуляторы, в виде монотерапии или в комбинации с одним или более дополнительными средствами, для лечения различных заболеваний центральной нервной системы (ЦНС), при которых желательно повышать стимуляцию sGC, или увеличивать концентрацию оксида азота (NO) или циклического гуанозин-3',5'-монофосфата (cGMP) или того и другого, или повышать регуляцию сигнального каскада NO.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662419059P | 2016-11-08 | 2016-11-08 | |
PCT/US2017/060299 WO2018089328A1 (en) | 2016-11-08 | 2017-11-07 | Treatment of cns diseases with sgc stimulators |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201991147A1 true EA201991147A1 (ru) | 2019-11-29 |
Family
ID=60452769
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201991147A EA201991147A1 (ru) | 2016-11-08 | 2017-11-07 | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC |
Country Status (17)
Country | Link |
---|---|
US (2) | US11690828B2 (ru) |
EP (1) | EP3538096B1 (ru) |
JP (2) | JP7150740B2 (ru) |
KR (1) | KR102475124B1 (ru) |
CN (1) | CN110267658B (ru) |
AU (2) | AU2017359018C1 (ru) |
BR (1) | BR112019009449A2 (ru) |
CA (1) | CA3042548A1 (ru) |
CL (1) | CL2019001256A1 (ru) |
EA (1) | EA201991147A1 (ru) |
IL (1) | IL266275B2 (ru) |
MA (1) | MA46752A (ru) |
MX (2) | MX2019005342A (ru) |
PH (1) | PH12019501016A1 (ru) |
SG (1) | SG10202104865UA (ru) |
TW (1) | TWI812601B (ru) |
WO (1) | WO2018089328A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019055859A1 (en) * | 2017-09-14 | 2019-03-21 | Ironwood Pharmaceuticals, Inc. | TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR |
CN112384220A (zh) | 2018-07-11 | 2021-02-19 | 塞科里昂医疗股份有限公司 | sGC刺激剂治疗线粒体障碍的用途 |
US20230012071A1 (en) * | 2019-12-05 | 2023-01-12 | Zydus Lifesciences Limited | Modified release pharmaceutical compositions of riociguat |
CN112924573B (zh) * | 2021-01-21 | 2022-01-04 | 山东英盛生物技术有限公司 | 一种阿比多尔、利巴韦林、氯喹的hplc-ms/ms检测方法 |
WO2023130028A1 (en) * | 2021-12-31 | 2023-07-06 | Tenax Therapeutics, Inc. | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
DE3660408D1 (en) | 1985-02-27 | 1988-08-25 | Oerlikon Buehrle Ag | Apparatus for measuring the vibrations of a spiral bevel gear transmission in a gear-testing machine |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | 1−(置換ベンジル)−3−(置換アリール)縮合ピラゾール類、その製造法及びその用途 |
US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
ATE309206T1 (de) | 1998-07-08 | 2005-11-15 | Sanofi Aventis Deutschland | Schwefel-substituierte sulfonylaminocarbonsäure n-arylamide, ihre herstellung, ihre anwendung und diese enthaltende pharmazeutische zusammensetzungen |
DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
ATE260642T1 (de) | 1998-12-17 | 2004-03-15 | Alza Corp | Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen |
US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
MXPA06001506A (es) | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa. |
DE102006020327A1 (de) * | 2006-04-27 | 2007-12-27 | Bayer Healthcare Ag | Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung |
WO2009032249A1 (en) | 2007-09-06 | 2009-03-12 | Merck & Co., Inc. | Soluble guanylate cyclase activators |
JP2011510082A (ja) | 2008-01-24 | 2011-03-31 | メルク・シャープ・エンド・ドーム・コーポレイション | アンジオテンシンii受容体拮抗薬 |
EP2373317B1 (en) | 2008-11-25 | 2016-12-14 | Merck Sharp & Dohme Corp. | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases |
CN102414194A (zh) | 2009-02-26 | 2012-04-11 | 默沙东公司 | 可溶性鸟苷酸环化酶激活剂 |
WO2011119518A1 (en) | 2010-03-25 | 2011-09-29 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
SG185777A1 (en) | 2010-05-27 | 2012-12-28 | Merck Sharp & Dohme | Soluble guanylate cyclase activators |
WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
MX2018007152A (es) * | 2015-12-14 | 2018-08-15 | Ironwood Pharmaceuticals Inc | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal. |
WO2017108441A1 (en) | 2015-12-22 | 2017-06-29 | Universiteit Maastricht | Treatment of cognitive impairment with cgc stimulator |
WO2017121700A1 (de) | 2016-01-15 | 2017-07-20 | Bayer Pharma Aktiengesellschaft | 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
CR20190101A (es) * | 2016-09-02 | 2019-07-04 | Ironwood Pharmaceuticals Inc | Estimuladores de sgc |
-
2017
- 2017-11-07 CN CN201780080543.0A patent/CN110267658B/zh active Active
- 2017-11-07 MA MA046752A patent/MA46752A/fr unknown
- 2017-11-07 TW TW106138467A patent/TWI812601B/zh active
- 2017-11-07 JP JP2019545723A patent/JP7150740B2/ja active Active
- 2017-11-07 IL IL266275A patent/IL266275B2/en unknown
- 2017-11-07 CA CA3042548A patent/CA3042548A1/en active Pending
- 2017-11-07 KR KR1020197016351A patent/KR102475124B1/ko active IP Right Grant
- 2017-11-07 WO PCT/US2017/060299 patent/WO2018089328A1/en active Application Filing
- 2017-11-07 EA EA201991147A patent/EA201991147A1/ru unknown
- 2017-11-07 BR BR112019009449A patent/BR112019009449A2/pt not_active IP Right Cessation
- 2017-11-07 AU AU2017359018A patent/AU2017359018C1/en active Active
- 2017-11-07 US US16/348,359 patent/US11690828B2/en active Active
- 2017-11-07 SG SG10202104865UA patent/SG10202104865UA/en unknown
- 2017-11-07 MX MX2019005342A patent/MX2019005342A/es unknown
- 2017-11-07 EP EP17804374.1A patent/EP3538096B1/en active Active
-
2019
- 2019-05-07 MX MX2022010852A patent/MX2022010852A/es unknown
- 2019-05-07 CL CL2019001256A patent/CL2019001256A1/es unknown
- 2019-05-08 PH PH12019501016A patent/PH12019501016A1/en unknown
-
2022
- 2022-08-08 JP JP2022126467A patent/JP2022160605A/ja active Pending
-
2023
- 2023-05-12 US US18/196,826 patent/US20230381153A1/en active Pending
- 2023-11-22 AU AU2023270267A patent/AU2023270267A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110267658A (zh) | 2019-09-20 |
AU2017359018A1 (en) | 2019-05-30 |
WO2018089328A1 (en) | 2018-05-17 |
TWI812601B (zh) | 2023-08-21 |
TW201822765A (zh) | 2018-07-01 |
EP3538096A1 (en) | 2019-09-18 |
BR112019009449A2 (pt) | 2019-07-30 |
SG10202104865UA (en) | 2021-06-29 |
MX2022010852A (es) | 2022-09-27 |
MA46752A (fr) | 2019-09-18 |
PH12019501016A1 (en) | 2019-09-09 |
JP2022160605A (ja) | 2022-10-19 |
JP7150740B2 (ja) | 2022-10-11 |
EP3538096C0 (en) | 2024-02-28 |
KR102475124B1 (ko) | 2022-12-08 |
US20230381153A1 (en) | 2023-11-30 |
AU2023270267A1 (en) | 2023-12-07 |
CL2019001256A1 (es) | 2019-10-04 |
WO2018089328A8 (en) | 2019-03-28 |
IL266275B1 (en) | 2023-08-01 |
AU2017359018C1 (en) | 2023-12-21 |
JP2019534327A (ja) | 2019-11-28 |
MX2019005342A (es) | 2019-10-02 |
AU2017359018B2 (en) | 2023-08-31 |
US11690828B2 (en) | 2023-07-04 |
CA3042548A1 (en) | 2018-05-17 |
IL266275A (en) | 2019-06-30 |
KR20190094167A (ko) | 2019-08-12 |
US20190343813A1 (en) | 2019-11-14 |
IL266275B2 (en) | 2023-12-01 |
EP3538096B1 (en) | 2024-02-28 |
CN110267658B (zh) | 2024-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201991147A1 (ru) | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ С ПОМОЩЬЮ СТИМУЛЯТОРОВ sGC | |
PH12019500461A1 (en) | Fused bicyclic sgc stimulators | |
EA201990235A1 (ru) | ТВЕРДЫЕ ФОРМЫ СТИМУЛЯТОРА sGC | |
MX2019004616A (es) | Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina. | |
PE20190910A1 (es) | Compuestos terapeuticos utiles para el tratamiento profilactico o terapeutico de una infeccion por el virus del vih | |
CO2018002060A2 (es) | Compuestos farmacéuticos | |
MX2022016405A (es) | Análogos de nucleósido de 1¿-ciano y usos de estos. | |
BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
BR112016003348A2 (pt) | composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade efetiva de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica | |
EA202091502A1 (ru) | СТИМУЛЯТОРЫ sGC | |
EA202191498A1 (ru) | 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение | |
EA201791348A1 (ru) | Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений | |
DOP2021000198A (es) | Compuestos y su uso en el tratamiento del cáncer | |
MX2021006156A (es) | Compuestos utiles en la terapia para el vih. | |
PH12019501017A1 (en) | Sgc stimulators | |
BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
MX2021002322A (es) | Nuevos metodos. | |
EA201792264A1 (ru) | Способы лечения воспалительных заболеваний | |
MX2021002017A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
EA202090164A1 (ru) | Изотретиноиновые перорально-слизистые композиции и способы их применения | |
BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
MX2021006012A (es) | Derivados de amino triazolo quinazolina 7-, 8-, y 10-sustituidos como antagonistas de receptor de adenosina, composiciones farmaceuticas y su uso. | |
MX2019015371A (es) | Derivados de dihidro-pirrolo-piridina. | |
EA201792170A1 (ru) | Производные индола |